Literature DB >> 21607632

Inpatient costs for people with type 1 and type 2 diabetes in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.

L Govan1, O Wu, A Briggs, H M Colhoun, J A McKnight, A D Morris, D W M Pearson, J R Petrie, N Sattar, S H Wild, R S Lindsay.   

Abstract

AIMS/HYPOTHESIS: The rising prevalence of diabetes worldwide has increased interest in the cost of diabetes. Inpatient costs for all people with diabetes in Scotland were investigated.
METHODS: The Scottish Care Information-Diabetes Collaboration (SCI-DC), a real-time clinical information system of almost all diagnosed cases of diabetes in Scotland, UK, was linked to data on all hospital admissions for people with diabetes. Inpatient stay costs were estimated using the 2007-2008 Scottish National Tariff. The probability of hospital admission and total annual cost of admissions were estimated in relation to age, sex, type of diabetes, history of vascular admission, HbA(1c), creatinine, body mass index and diabetes duration.
RESULTS: In Scotland during 2005-2007, 24,750 people with type 1 and 195,433 people with type 2 diabetes were identified, accounting for approximately 4.3% of the total Scottish population (5.1 million). The estimated total annual cost of admissions for all people diagnosed with type 1 and type 2 diabetes was £26 million and £275 million, respectively, approximately 12% of the total Scottish inpatient expenditure (£2.4 billion). Sex, increasing age, serum creatinine, previous vascular history and HbA(1c) (the latter differentially in type 1 and type 2) were all associated with likelihood and total annual cost of admission. CONCLUSIONS/
INTERPRETATION: Diabetes inpatient expenditure accounted for 12% of the total Scottish inpatient expenditure, whilst people with diabetes account for 4.3% of the population. Of the modifiable risk factors, HbA(1c) was the most important driver of cost in type 1 diabetes.

Entities:  

Mesh:

Year:  2011        PMID: 21607632      PMCID: PMC4209853          DOI: 10.1007/s00125-011-2176-7

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  12 in total

1.  Estimated costs of acute hospital care for people with diabetes in the United Kingdom: a routine record linkage study in a large region.

Authors:  C Ll Morgan; J R Peters; S Dixon; C J Currie
Journal:  Diabet Med       Date:  2010-09       Impact factor: 4.359

2.  The cost of treating type 2 diabetes (CODEIRE).

Authors:  J J Nolan; D O'Halloran; T J McKenna; R Firth; S Redmond
Journal:  Ir Med J       Date:  2006 Nov-Dec

3.  Health care use of individuals with diabetes in an employer-based insurance population.

Authors:  S B Laditka; M P Mastanduno; J N Laditka
Journal:  Arch Intern Med       Date:  2001-05-28

4.  Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study.

Authors:  Craig J Currie; John R Peters; Aodán Tynan; Marc Evans; Robert J Heine; Oswaldo L Bracco; Tony Zagar; Chris D Poole
Journal:  Lancet       Date:  2010-01-26       Impact factor: 79.321

5.  The cost of insulin-dependent diabetes mellitus (IDDM) in England and Wales.

Authors:  A Gray; P Fenn; A McGuire
Journal:  Diabet Med       Date:  1995-12       Impact factor: 4.359

6.  Hospital in-patient statistics underestimate the morbidity associated with diabetes mellitus.

Authors:  P J Leslie; A W Patrick; D A Hepburn; I J Scougal; B M Frier
Journal:  Diabet Med       Date:  1992-05       Impact factor: 4.359

7.  Identifying undiagnosed diabetes: cross-sectional survey of 3.6 million patients' electronic records.

Authors:  Tim A Holt; David Stables; Julia Hippisley-Cox; Shaun O'Hanlon; Azeem Majeed
Journal:  Br J Gen Pract       Date:  2008-03       Impact factor: 5.386

8.  The cost of diabetes.

Authors:  K Gerard; C Donaldson; A K Maynard
Journal:  Diabet Med       Date:  1989-03       Impact factor: 4.359

9.  Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.

Authors:  H M Colhoun
Journal:  Diabetologia       Date:  2009-07-15       Impact factor: 10.122

10.  Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies.

Authors:  Gary Whitlock; Sarah Lewington; Paul Sherliker; Robert Clarke; Jonathan Emberson; Jim Halsey; Nawab Qizilbash; Rory Collins; Richard Peto
Journal:  Lancet       Date:  2009-03-18       Impact factor: 79.321

View more
  5 in total

1.  The cost of type 1 diabetes: a nationwide multicentre study in Brazil.

Authors:  Roberta Arnoldi Cobas; Marcos Bosi Ferraz; Alessandra Saldanha de Mattos Matheus; Lucianne Righeti Monteiro Tannus; Carlos Antonio Negrato; Luiz Antonio de Araujo; Sergio Atala Dib; Marilia Brito Gomes
Journal:  Bull World Health Organ       Date:  2013-04-04       Impact factor: 9.408

2.  The impact of adherence to screening guidelines and of diabetes clinics referral on morbidity and mortality in diabetes.

Authors:  Carlo Giorda; Roberta Picariello; Elisa Nada; Barbara Tartaglino; Lisa Marafetti; Giuseppe Costa; Roberto Gnavi
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

Review 3.  Biomarkers in diabetic retinopathy and the therapeutic implications.

Authors:  Katarzyna Zorena; Dorota Raczyńska; Krystyna Raczyńska
Journal:  Mediators Inflamm       Date:  2013-11-07       Impact factor: 4.711

4.  Direct diabetes-related costs in young patients with early-onset, long-lasting type 1 diabetes.

Authors:  Christina Bächle; Andrea Icks; Klaus Straßburger; Marion Flechtner-Mors; Andreas Hungele; Peter Beyer; Kerstin Placzek; Ulrich Hermann; Andrea Schumacher; Markus Freff; Anna Stahl-Pehe; Reinhard W Holl; Joachim Rosenbauer
Journal:  PLoS One       Date:  2013-08-13       Impact factor: 3.240

5.  A post COVID-19 'Marshall Plan' for type 2 diabetes.

Authors:  John R Petrie; James G Boyle; Kashif Ali; Christopher Smith; Deborah Morrison; Partha Kar
Journal:  Diabet Med       Date:  2020-11-17       Impact factor: 4.213

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.